{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:44:00Z","timestamp":1793169840479,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40122-022-00417-6","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T10:02:21Z","timestamp":1659261741000},"page":"1483-1491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-6936","authenticated-orcid":false,"given":"Carl H.","family":"G\u00f6bel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Karstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cirkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"M\u00fcnte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,31]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3315\/jdcr.2015.1190","volume":"9","author":"I Bulur","year":"2015","unstructured":"Bulur I, Keseroglu HO, Saracoglu ZN, et al. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) associated with infliximab. J Dermatol Case Rep. 2015;9:12\u20134.","journal-title":"J Dermatol Case Rep"},{"issue":"3185\u20133189","key":"417_CR2","volume":"8","author":"T De Risi-Pugliese","year":"2020","unstructured":"De Risi-Pugliese T, Barailler H, Hamelin A, et al. Symmetrical drug-related intertriginous and flexural exanthema: a little-known drug allergy. J Allergy Clin Immunol Pract. 2020;8(3185\u20133189): e3184.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"417_CR3","unstructured":"Harbaoui S, Litaiem N. Symmetrical drug-related intertriginous and flexural exanthema. In: StatPearls. Treasure Island; 2022."},{"key":"417_CR4","volume":"8","author":"O Lima Miranda","year":"2021","unstructured":"Lima Miranda O, Martins J, Almeida A, et al. Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome). Eur J Case Rep Intern Med. 2021;8: 003029.","journal-title":"Eur J Case Rep Intern Med"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s13312-020-2059-4","volume":"57","author":"S Neema","year":"2020","unstructured":"Neema S, Shaw SC, Gopalakrishnan S. Symmetrical drug-related intertriginous and flexural exanthema. Indian Pediatr. 2020;57:1093.","journal-title":"Indian Pediatr"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.5021\/ad.2018.30.5.606","volume":"30","author":"J Seok","year":"2018","unstructured":"Seok J, Kim JM, Park KY, et al. Symmetrical drug-related intertriginous and flexural exanthema: two cases and brief literature review. Ann Dermatol. 2018;30:606\u20139.","journal-title":"Ann Dermatol"},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.0105-1873.2004.00445.x","volume":"51","author":"P H\u00e4usermann","year":"2004","unstructured":"H\u00e4usermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51:297\u2013310.","journal-title":"Contact Dermatitis"},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/15569527.2015.1067227","volume":"35","author":"AS Karadag","year":"2016","unstructured":"Karadag AS, Ozlu E, Akdeniz N, et al. Oral mucosal involvement and petechial lesions: a SDRIFE case with unusual findings. Cutan Ocul Toxicol. 2016;35:157\u20139.","journal-title":"Cutan Ocul Toxicol"},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/ACI.0b013e3283489d5f","volume":"11","author":"SC Tan","year":"2011","unstructured":"Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol. 2011;11:313\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"417_CR10","volume":"9","author":"DG Li","year":"2017","unstructured":"Li DG, Thomas C, Weintraub GS, et al. Symmetrical drug-related intertriginous and flexural exanthema induced by doxycycline. Cureus. 2017;9: e1836.","journal-title":"Cureus"},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14740338.2021.1933941","volume":"20","author":"CI Deligianni","year":"2021","unstructured":"Deligianni CI, Mitsikostas DD, Ashina M. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. Expert Opin Drug Saf. 2021;20:867\u201376.","journal-title":"Expert Opin Drug Saf"},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Prim. 2022;8:2.","journal-title":"Nat Rev Dis Prim"},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","volume":"79","author":"M Ashina","year":"2022","unstructured":"Ashina M, Goadsby PJ, Dodick DW, et al. Assessment of erenumab safety and efficacy in patients with migraine with and without aura: a secondary analysis of randomized clinical trials. JAMA Neurol. 2022;79:159\u201368.","journal-title":"JAMA Neurol"},{"key":"417_CR14","doi-asserted-by":"crossref","unstructured":"De Vries Lentsch S, Al-Hassany L, Ferrari MD, et al. CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. J Neurol Neurosurg Psychiatry. 202;93:911\u201312.","DOI":"10.1136\/jnnp-2021-327992"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337.","journal-title":"Cephalalgia"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332.","journal-title":"N Engl J Med"},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95:e469\u201379.","journal-title":"Neurology"},{"key":"417_CR18","doi-asserted-by":"crossref","unstructured":"Liang D, Sessa M. Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Expert Opin Drug Saf. 2022;1\u20136.","DOI":"10.1080\/14740338.2022.2049231"},{"key":"417_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bedussi F, Gobbi C, et al. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia. 2021;41:789\u201398.","journal-title":"Cephalalgia"},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-022-01426-8","volume":"23","author":"H Schenk","year":"2022","unstructured":"Schenk H, Holle D, Nsaka M, et al. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study. J Headache Pain. 2022;23:55.","journal-title":"J Headache Pain"},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-021-00469-8","volume":"35","author":"M Sessa","year":"2021","unstructured":"Sessa M, Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs. 2021;35:215\u201327.","journal-title":"BioDrugs"},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425\u201334.","journal-title":"Lancet Neurol"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39:1455\u201364.","journal-title":"Cephalalgia"},{"key":"417_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00482-018-0355-x","volume":"33","author":"H G\u00f6bel","year":"2019","unstructured":"G\u00f6bel H, Frank B, Heinze A, et al. Healthcare behavior of migraine and headache patients when treatment is accompanied by the digital migraine app. Schmerz. 2019;33:147\u201355.","journal-title":"Schmerz"},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/jocd.13863","volume":"20","author":"R Mofarrah","year":"2021","unstructured":"Mofarrah R, Mofarrah R, Kranke B, et al. First report of tamoxifen-induced baboon syndrome. J Cosmet Dermatol. 2021;20:2574\u20138.","journal-title":"J Cosmet Dermatol"},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdcr.2021.10.016","volume":"18","author":"J Hai","year":"2021","unstructured":"Hai J, Shawa H, Kim-Lim P, et al. Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: a report of 2 cases. JAAD Case Rep. 2021;18:57\u201360.","journal-title":"JAAD Case Rep"},{"key":"417_CR27","unstructured":"Nicolas S, Nicolas D. Triptans. In: StatPearls. StatPearls Publishing, Treasure Island; 2022."},{"key":"417_CR28","doi-asserted-by":"crossref","unstructured":"Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug\u2013drug interactions of new anti-migraine drugs-lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12:1180.","DOI":"10.3390\/pharmaceutics12121180"},{"key":"417_CR29","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280\u20137.","journal-title":"Lancet"},{"key":"417_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021;61:653\u201361.","journal-title":"Headache"},{"key":"417_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40:543\u201353.","journal-title":"Cephalalgia"},{"key":"417_CR32","doi-asserted-by":"crossref","unstructured":"Viudez-Martinez A, Pascual-Carrasco A, Beltran-Blasco I, et al. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: a retrospective cohort study. J Clin Pharm Ther. 2022;47(6):814\u201323.","DOI":"10.1111\/jcpt.13620"},{"key":"417_CR33","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhang F, Starcevic Manning M et al. Immunogenicity of erenumab: a pooled analysis of six placebo-controlled trials with long-term extensions. Cephalalgia. 2022;3331024221075621.","DOI":"10.1177\/03331024221075621"},{"key":"417_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018483","volume":"98","author":"C Zhu","year":"2019","unstructured":"Zhu C, Guan J, Xiao H, et al. Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2019;98:e18483.","journal-title":"Medicine (Baltimore)"},{"key":"417_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5070\/D32WS5H2S0","volume":"15","author":"SB Elmariah","year":"2009","unstructured":"Elmariah SB, Cheung W, Wang N, et al. Systemic drug-related intertriginous and flexural exanthema (SDRIFE). Dermatol Online J. 2009;15:3.","journal-title":"Dermatol Online J"},{"key":"417_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/11539080-000000000-00000","volume":"12","author":"M Winnicki","year":"2011","unstructured":"Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12:171\u201380.","journal-title":"Am J Clin Dermatol"},{"key":"417_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/15569527.2019.1594874","volume":"38","author":"B Yalici-Armagan","year":"2019","unstructured":"Yalici-Armagan B, Ayanoglu BT, Demirdag HG. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. Cutan Ocul Toxicol. 2019;38:261\u20136.","journal-title":"Cutan Ocul Toxicol"},{"key":"417_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/ijd.13565","volume":"56","author":"SY Yang","year":"2017","unstructured":"Yang SY, Lan CC, Hu SC. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. Int J Dermatol. 2017;56:571\u20132.","journal-title":"Int J Dermatol"},{"key":"417_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cod.13084","volume":"79","author":"L Nespoulous","year":"2018","unstructured":"Nespoulous L, Matei I, Charissoux A, et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis. 2018;79:378\u201380.","journal-title":"Contact Dermatitis"},{"key":"417_CR40","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/ijd.14059","volume":"57","author":"JG Labadie","year":"2018","unstructured":"Labadie JG, Florek AG, Croitoru A, et al. First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. Int J Dermatol. 2018;57:e68\u201370.","journal-title":"Int J Dermatol"},{"key":"417_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jdcr.2015.03.007","volume":"1","author":"T Huynh","year":"2015","unstructured":"Huynh T, Hughey LC, Mckay K, et al. Systemic drug-related intertriginous and flexural exanthema from radio contrast media: a series of 3 cases. JAAD Case Rep. 2015;1:147\u20139.","journal-title":"JAAD Case Rep"},{"key":"417_CR42","first-page":"657","volume":"15","author":"N Magnolo","year":"2017","unstructured":"Magnolo N, Metze D, Stander S. Pustulobullose Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). J Dtsch Dermatol Ges. 2017;15:657\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"key":"417_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/apha.12442","volume":"213","author":"RD Granstein","year":"2015","unstructured":"Granstein RD, Wagner JA, Stohl LL, et al. Calcitonin gene-related peptide: key regulator of cutaneous immunity. Acta Physiol (Oxf). 2015;213:586\u201394.","journal-title":"Acta Physiol (Oxf)"},{"key":"417_CR44","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/jid.2012.464","volume":"133","author":"D Roggenkamp","year":"2013","unstructured":"Roggenkamp D, Kopnick S, Stab F, et al. Epidermal nerve fibers modulate keratinocyte growth via neuropeptide signaling in an innervated skin model. J Investig Dermatol. 2013;133:1620\u20138.","journal-title":"J Investig Dermatol"},{"key":"417_CR45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.biopha.2008.02.003","volume":"62","author":"M Toda","year":"2008","unstructured":"Toda M, Suzuki T, Hosono K, et al. Roles of calcitonin gene-related peptide in facilitation of wound healing and angiogenesis. Biomed Pharmacother. 2008;62:352\u20139.","journal-title":"Biomed Pharmacother"},{"key":"417_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/0333102420933571","volume":"40","author":"S Wurthmann","year":"2020","unstructured":"Wurthmann S, Nagel S, Hadaschik E, et al. Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: a case report. Cephalalgia. 2020;40:1255\u201360.","journal-title":"Cephalalgia"},{"key":"417_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-021-01330-7","volume":"22","author":"JC Ray","year":"2021","unstructured":"Ray JC, Allen P, Bacsi A, et al. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22:121.","journal-title":"J Headache Pain"},{"key":"417_CR48","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","volume":"92","author":"JC Ray","year":"2021","unstructured":"Ray JC, Kapoor M, Stark RJ, et al. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J Neurol Neurosurg Psychiatry. 2021;92:1325\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-022-00417-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T18:24:08Z","timestamp":1667672648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-022-00417-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,31]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s40122-022-00417-6","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,31]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}